StockData

CervoMed vs Serina Therapeutics

CRVO and SER side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRVO and SER compare

Serina Therapeutics is the larger company, worth 1.4 times as much as CervoMed ($35.3M against $25.6M).

CervoMed scores higher on the StockData Score (6 against 2 for Serina Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRVOSER
Size and price
Market cap$25.6M$35.3M
Share price$1.69$1.39
Change, 1 year−77.2%−65.4%
Change, 5 years−94.2%−95.0%
Beta (5Y)0.550.35
Employees1516
StockData Score
Total score6 (better)2
Valuation score1 (better)0
Growth score01 (better)
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S2928×–
P/B1.5× (better)2.5×
FCF yield–−64.7%
Growth
Revenue growth (TTM)−99.9%–
Revenue growth, 5Y average–−18.5%
Profitability
Operating margin−334925%–
Net margin−326823%–
Return on equity−132% (better)−312%
Financial health
Debt / equity0.00–
Current ratio5.37 (better)4.62
Altman Z-score−7.44−1.86 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions11.6%5.5%
Held by insiders36.9%49.7%
Insider net buying, 12 months$3.0M (better)−$232K
Short interest, % of float12.7%0.37%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.